Tekla Life Sciences Investors (HQL) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear

Tekla Life Sciences Inves...

NYSE: HQL · Real-Time Price · USD
14.31
0.20 (1.42%)
At close: Sep 05, 2025, 3:58 PM
14.34
0.23%
After-hours: Sep 05, 2025, 07:45 PM EDT

Tekla Life Sciences Investors Income Statement

Financials in USD. Fiscal year is October - September.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Sep 30, 2024 Sep 30, 2023 Sep 30, 2022 Sep 30, 2021
Revenue
86.69M 39.39M 31.86M 45.02M
Cost of Revenue
n/a 5.24M 5.55M 6.08M
Gross Profit
86.69M 18.28M 26.31M 38.95M
Operating Income
85.3M -5.24M -104.6M 64.53M
Interest Income
1.04M 204.45K 50.09K n/a
Pretax Income
85.3M 22.35M -104.6M 64.53M
Net Income
85.3M 22.35M -104.6M 64.53M
Selling & General & Admin
1.33M 903.14K 1.08M 844.02K
Research & Development
n/a n/a -3.28 n/a
Other Expenses
56.66K 268.31K 275.97K 313.69K
Operating Expenses
1.39M 1.17M 1.35M 1.16M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
1.39M 17.03M 136.47M -19.51M
Income Tax Expense
n/a n/a n/a n/a
Shares Outstanding (Basic)
28.06M 28.29M 25.68M 24.26M
Shares Outstanding (Diluted)
28.06M 28.29M 25.68M 24.26M
EPS (Basic)
3.04 0.79 -4.07 2.66
EPS (Diluted)
3.04 0.79 -4.07 2.66
EBITDA
85.3M 22.35M -104.61M 64.54M
EBIT
85.3M 22.35M -104.61M 64.54M
Depreciation & Amortization
1.92M 27.6M 2.99M 4.14M